Month: September 2020

 Saint-Herblain (France), 18 septembre 2020 – Valneva SE (“Valneva” ou le Groupe), société spécialisée dans les vaccins contre des maladies générant d’importants besoins médicaux, a annoncé aujourd’hui le départ à la retraite de son directeur financier David Lawrence à la fin de l’année 2020.Valneva a lancé un processus de recrutement d’un nouveau directeur financier auprès d’une agence de recrutement internationale avec pour objectif l’arrivée d’un nouveau directeur financier au premier trimestre 2021.Jusqu’à la fin de l’année, afin d’assurer une transition en douceur, David Lawrence assurera un processus de transfert de responsabilités à Manfred Tiefenbacher, VP Finance, qui sera responsable de toutes les activités financières opérationnelles.David Lawrence a de plus accepté de continuer à conseiller le CEO de Valneva au début...

ROTTERDAM, The Netherlands (18 September 2020, 07:00 CET) – IMCD N.V. (“IMCD” or the “Company”), a leading distributor of speciality chemicals and ingredients, today announces that it has acquired 100% of the share capital of Oy Kokko-Fiber Ab (“Kokko-Fiber”), a leading supplier of fiber-reinforced plastic composite materials in Finland.Kokko-Fiber, founded in 1994, serves a broad customer base that includes many of the largest Finnish companies that use fiber-reinforced plastics in their operations. The company has five employees and generated a revenue of €9.0 million in 2019.Attached, please find the release in pdf format.– xxx –About IMCD N.V. IMCD is a market leader in the sales, marketing and distribution of speciality chemicals and food ingredients. Its result-driven professionals provide market-focused solutions to...

EMPACTA is the first global phase III trial to show efficacy with Actemra/RoActemra in COVID-19 associated pneumonia and the first with a focus on enrolling largely underserved and minority patientsThere was no statistical difference in mortality between patients who received Actemra/RoActemra or placeboRoche plans to share these results with health authorities, including the US FDABasel, 18 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III EMPACTA study met its primary endpoint, showing that patients with COVID-19 associated pneumonia who received Actemra®/RoActemra® (tocilizumab) plus standard of care were 44% less likely to progress to mechanical ventilation or death compared to patients who received placebo plus standard of care (log-rank p-value = 0.0348; HR [95% CI] = 0.56 [0.32, 0.97])....

 COMPASS Pathways announces pricing of upsized initial public offeringLondon, UK – September 18, 2020COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of its upsized initial public offering in the United States of 7,500,000 American Depositary Shares (“ADSs”) representing 7,500,000 ordinary shares at an initial public offering price of $17.00 per ADS for total gross proceeds of $127.5 million. All ADSs sold in the offering were offered by COMPASS. The ADSs are expected to begin trading on the Nasdaq Global Select Market on September 18, 2020 under the ticker symbol “CMPS.” The offering is expected to close on or about September 22, 2020, subject to the satisfaction of customary closing conditions....

Attached is information regarding a transaction between a primary insider and a  financially connected party.  Attachments201809 Bogi Nils – Sala201809 Möskvi – Kaup

Attached is information regarding a transaction between financially connected parties of a primary insider.Attachments201809 Mánaþing ehf – Kaup201809 Sólþing ehf – Sala

Attached is information regarding transactions of board members and senior managers, along with their financially connected parties, in Icelandair Group‘s share offering.Attachments201709 Akurrif – Kaup201709 Brekkumýri – Kaup201709 John F Thomas – Kaup201709 Mánaþing – Kaup201709 Möskvi – Kaup201709 Náttúlfur ehf – Kaup201709 Svafa Grönfeldt – Kaup201709 Viðunandi ehf – Kaup2009017 EFIA -Kaup2009017 Hvarhylur – Kaup2009017 Jú ehf – Kaup2009017 Skeljungur – Kaup201709 Ting ehf – Kaup2009017 Hermann Árnason – Kaup

BUFORD, Georgia, Sept. 17, 2020 (GLOBE NEWSWIRE) — OneWater Marine Inc. (NASDAQ: ONEW) (“OneWater” or the “Company”) announced today the pricing of an underwritten public offering of 3,170,868 shares of its Class A common stock, par value $0.01 per share (“Class A common stock”), at $20.00 per share. The Company is offering 425,000 shares of its Class A common stock, and the selling stockholders named in the registration statement on Form S-1 (the “registration statement”) previously filed with the Securities and Exchange Commission (the “SEC”) are offering 2,745,868 shares of OneWater’s Class A common stock. In addition, an affiliate of Goldman Sachs & Co. LLC has granted the underwriters a 30-day option to purchase up to an additional 475,630 shares of OneWater’s Class A common stock. The offering is expected to close on...

Three complete responses (complete disappearance of all lesions) reported: two in 2nd line head and neck squamous cell carcinoma (HNSCC) and one in 1st line non-small cell lung cancer (NSCLC)Five responses in patients (both indications) with negative (< 1%) or moderate PD-L1 expression where pembrolizumab monotherapy does not work wellMedian Progression Free Survival (PFS) of 4.3 months in HNSCC patients and 47% progression free at 6 months in this very aggressive late stage diseasePFS continues to improve in 1st line NSCLC patients with median PFS of 11.8 months and patients with responses have durable onesSYDNEY, Australia, Sept. 18, 2020 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study. The data was presented in two poster presentations at the ESMO...

SEATTLE, Sept. 17, 2020 (GLOBE NEWSWIRE) — Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Athira. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Athira, are expected to be $204.0 million. Athira’s common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “ATHA” on September 18, 2020. The offering is expected to close on September 22, 2020, subject to satisfaction of...